- Markets
- Healthcare
- HIKAL
HIKAL
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Hikal falls after unit gets 6 observations from USFDA
** Shares of pharmaceuticals company Hikal HIKA.NS fall 5.1% to 357.55 rupees
** Co says US Food and Drug Administration (USFDA) concludes inspection at Jigani unit in Bengaluru with six observations
** Co did not specify what the observations are
** Trading vol at 249,574 shares, compared to 30-day avg of 265,596 shares
** Stock extends YTD losses to 8.4%
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
** Shares of pharmaceuticals company Hikal HIKA.NS fall 5.1% to 357.55 rupees
** Co says US Food and Drug Administration (USFDA) concludes inspection at Jigani unit in Bengaluru with six observations
** Co did not specify what the observations are
** Trading vol at 249,574 shares, compared to 30-day avg of 265,596 shares
** Stock extends YTD losses to 8.4%
(Reporting by Meenakshi Maidas in Bengaluru)
(([email protected];))
Hikal Dec-Quarter Consol Profit 172 Million Rupees
Feb 4 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL DEC-QUARTER CONSOL PROFIT 172 MILLION RUPEES
HIKAL DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 4.48 BILLION RUPEES
Source text: ID:nBSE34JySy
Further company coverage: HIKA.NS
(([email protected];))
Feb 4 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL DEC-QUARTER CONSOL PROFIT 172 MILLION RUPEES
HIKAL DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 4.48 BILLION RUPEES
Source text: ID:nBSE34JySy
Further company coverage: HIKA.NS
(([email protected];))
Hikal Says Sept-Quarter Consol Profit At 183 Million Rupees
Nov 12 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL LTD SEPT-QUARTER CONSOL PROFIT 183 MILLION RUPEES
HIKAL LTD SEPT-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 4.53 BILLION RUPEES
Source text: ID:nBSEZnM9V
Further company coverage: HIKA.NS
(([email protected];))
Nov 12 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL LTD SEPT-QUARTER CONSOL PROFIT 183 MILLION RUPEES
HIKAL LTD SEPT-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 4.53 BILLION RUPEES
Source text: ID:nBSEZnM9V
Further company coverage: HIKA.NS
(([email protected];))
India's Ami Organics up as facility clears Japan drug regulator's inspection
** Shares of pharmaceutical intermediates maker Ami Organics AMIO.NS rise 3.8% before trimming gains; last up 1.4%
** Co on Friday said Japan's drug regulator - the Pharmaceutical and Medical Devices Agency - inspected co's manufacturing facility in Surat for good manufacturing practices and concluded without any critical observations
** Inspected facility involved in making intermediates of active pharmaceutical ingredients
** Co exports products to Japan among other regions; its export revenue contributed to 56% of the overall rev in FY24
** Stock up 10% YTD, while smaller peer Hikal HIKA.NS is down 2.2% so far this year
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of pharmaceutical intermediates maker Ami Organics AMIO.NS rise 3.8% before trimming gains; last up 1.4%
** Co on Friday said Japan's drug regulator - the Pharmaceutical and Medical Devices Agency - inspected co's manufacturing facility in Surat for good manufacturing practices and concluded without any critical observations
** Inspected facility involved in making intermediates of active pharmaceutical ingredients
** Co exports products to Japan among other regions; its export revenue contributed to 56% of the overall rev in FY24
** Stock up 10% YTD, while smaller peer Hikal HIKA.NS is down 2.2% so far this year
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
India's Shelter Pharma up after order win
** Shares of Shelter Pharma SHEH.BO up 7.6% to 52.7 rupees, its biggest intraday pct gain since May 3
** Pharmaceutical co got order worth $120,000 from Berlin International Medical Co
** SHEH is trading below its key 50-, 100- moving avgs
** Stock is down 4% YTD, compared to a ~3% surge and 6% decline in larger peers Ami Organics AMIO.NS and Hikal Limited HIKA.NS, respectively
** Stock is ~32% up from last August, when it made its market debut
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Shelter Pharma SHEH.BO up 7.6% to 52.7 rupees, its biggest intraday pct gain since May 3
** Pharmaceutical co got order worth $120,000 from Berlin International Medical Co
** SHEH is trading below its key 50-, 100- moving avgs
** Stock is down 4% YTD, compared to a ~3% surge and 6% decline in larger peers Ami Organics AMIO.NS and Hikal Limited HIKA.NS, respectively
** Stock is ~32% up from last August, when it made its market debut
(Reporting by Aleef Jahan in Bengaluru)
Hikal Says Anticipate Favorable Shift In Market Dynamics Over Mid To Long Term
May 9 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL LTD - ANTICIPATE FAVORABLE SHIFT IN MARKET DYNAMICS OVER MID TO LONG TERM
Source text for Eikon: ID:nBSE6F2shJ
Further company coverage: HIKA.NS
(([email protected];))
May 9 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL LTD - ANTICIPATE FAVORABLE SHIFT IN MARKET DYNAMICS OVER MID TO LONG TERM
Source text for Eikon: ID:nBSE6F2shJ
Further company coverage: HIKA.NS
(([email protected];))
Hikal Ltd- MD Was Not Detained, Taken Into Police Custody
March 5 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL LTD- MD WAS NOT DETAINED AND NEITHER TAKEN INTO CUSTODY
HIKAL LTD- AUTHORITIES HAVE MADE A SYMBOLIC ARREST ON PAPER OF MD, RELEASED ON BAIL IN 2022 CASE
Source text for Eikon: ID:nNSE2Kydl5
Further company coverage: HIKA.NS
(([email protected];))
March 5 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL LTD- MD WAS NOT DETAINED AND NEITHER TAKEN INTO CUSTODY
HIKAL LTD- AUTHORITIES HAVE MADE A SYMBOLIC ARREST ON PAPER OF MD, RELEASED ON BAIL IN 2022 CASE
Source text for Eikon: ID:nNSE2Kydl5
Further company coverage: HIKA.NS
(([email protected];))
Hikal Says Bombay High Court Disposed Of Co's Writ Petition Challenging Jurisdiction Of Principal Bench Of Ngt
Feb 23 (Reuters) - Hikal Ltd HIKA.NS:
BOMBAY HIGH COURT DISPOSED OF WRIT PETITION OF CO CHALLENGING JURISDICTION OF PRINCIPAL BENCH OF NGT
COURT GRANTED LIBERTY TO CO TO SEEK REMEDIES AS AVAILABLE UNDER LAW
Source text for Eikon: ID:nBSE2zlrr1
Further company coverage: HIKA.NS
(([email protected];))
Feb 23 (Reuters) - Hikal Ltd HIKA.NS:
BOMBAY HIGH COURT DISPOSED OF WRIT PETITION OF CO CHALLENGING JURISDICTION OF PRINCIPAL BENCH OF NGT
COURT GRANTED LIBERTY TO CO TO SEEK REMEDIES AS AVAILABLE UNDER LAW
Source text for Eikon: ID:nBSE2zlrr1
Further company coverage: HIKA.NS
(([email protected];))
India's Hikal falls as Q3 profit slumps
** Shares of Hikal HIKA.NS down 2.9% to 288.8 rupees
** HIKA slid 3.8% earlier in the day to hit session's low at 286 rupees
** Chemical maker's Q3 consol net profit slumped ~39%, rev from ops dropped 17%
** More than 308,000 shares changed hands by 12:50 p.m. IST vs 30-day avg of 310,603
** So far this year stock has fallen ~5% after a 26% drop in 2023 - its second straight annual loss
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
** Shares of Hikal HIKA.NS down 2.9% to 288.8 rupees
** HIKA slid 3.8% earlier in the day to hit session's low at 286 rupees
** Chemical maker's Q3 consol net profit slumped ~39%, rev from ops dropped 17%
** More than 308,000 shares changed hands by 12:50 p.m. IST vs 30-day avg of 310,603
** So far this year stock has fallen ~5% after a 26% drop in 2023 - its second straight annual loss
(Reporting by Hritam Mukherjee in Bengaluru)
(([email protected];))
Hikal Dec-Quarter Consol Net Profit Falls
Feb 8 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL DEC-QUARTER CONSOL NET PROFIT 161.4 MILLION RUPEES VERSUS 264.1 MILLION RUPEES
HIKAL DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 4.48 BILLION RUPEES VERSUS 5.40 BILLION RUPEES
Source text for Eikon: ID:nNSE9qYlQ8
Further company coverage: HIKA.NS
(([email protected];;))
Feb 8 (Reuters) - Hikal Ltd HIKA.NS:
HIKAL DEC-QUARTER CONSOL NET PROFIT 161.4 MILLION RUPEES VERSUS 264.1 MILLION RUPEES
HIKAL DEC-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 4.48 BILLION RUPEES VERSUS 5.40 BILLION RUPEES
Source text for Eikon: ID:nNSE9qYlQ8
Further company coverage: HIKA.NS
(([email protected];;))
Hikal Says Gujarat Pollution Control Board Directing Co To Pay 174.5 Mln Rupees
Dec 29 (Reuters) - Hikal Ltd HIKA.NS:
GUJARAT POLLUTION CONTROL BOARD DIRECTING CO TO PAY 174.5 MILLION RUPEES
Source text for Eikon: ID:nBSE7jmgZZ
Further company coverage: HIKA.NS
(([email protected];;))
Dec 29 (Reuters) - Hikal Ltd HIKA.NS:
GUJARAT POLLUTION CONTROL BOARD DIRECTING CO TO PAY 174.5 MILLION RUPEES
Source text for Eikon: ID:nBSE7jmgZZ
Further company coverage: HIKA.NS
(([email protected];;))
India's Hikal Posts June-Quarter Consol Net Profit
Aug 8 (Reuters) - Hikal Ltd HIKA.NS:
INDIA'S HIKAL LTD JUNE-QUARTER CONSOL NET PROFIT 69.2 MILLION RUPEES VERSUS LOSS 88.6 MILLION RUPEES
HIKAL LTD JUNE-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 3.88 BILLION RUPEES VERSUS 3.79 BILLION RUPEES
Source text for Eikon: ID:nBSE5Lg0Hp
Further company coverage: HIKA.NS
(([email protected];))
Aug 8 (Reuters) - Hikal Ltd HIKA.NS:
INDIA'S HIKAL LTD JUNE-QUARTER CONSOL NET PROFIT 69.2 MILLION RUPEES VERSUS LOSS 88.6 MILLION RUPEES
HIKAL LTD JUNE-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 3.88 BILLION RUPEES VERSUS 3.79 BILLION RUPEES
Source text for Eikon: ID:nBSE5Lg0Hp
Further company coverage: HIKA.NS
(([email protected];))
India's Hikal rises 12% as quarterly profit leaps
** Shares of Hikal Ltd HIKA.NS up as much as 12.1% to 317.50 rupees, their highest since March 16
** Stock rises after six consecutive sessions of declines
** Chemicals manufacturer posted a ~74% YoY surge in its March-qtr net profit, while revenue from ops rose 7.4% YoY
** Over 2.2 mln shares change hands by 09:46 a.m. IST, 10.4x the 30-day moving avg
** Stock down ~23% YTD vs a 22% decline last year
(Reporting by Kashish Tandon in Bengaluru)
** Shares of Hikal Ltd HIKA.NS up as much as 12.1% to 317.50 rupees, their highest since March 16
** Stock rises after six consecutive sessions of declines
** Chemicals manufacturer posted a ~74% YoY surge in its March-qtr net profit, while revenue from ops rose 7.4% YoY
** Over 2.2 mln shares change hands by 09:46 a.m. IST, 10.4x the 30-day moving avg
** Stock down ~23% YTD vs a 22% decline last year
(Reporting by Kashish Tandon in Bengaluru)
India's Hikal March-Quarter Consol Profit Rises
May 29 (Reuters) - Hikal Ltd HIKA.NS:
MARCH-QUARTER CONSOL PROFIT 360 MILLION RUPEES VERSUS PROFIT 207.1 MILLION RUPEES
MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 5.45 BILLION RUPEES VERSUS 5.02 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: HIKA.NS
(([email protected];))
May 29 (Reuters) - Hikal Ltd HIKA.NS:
MARCH-QUARTER CONSOL PROFIT 360 MILLION RUPEES VERSUS PROFIT 207.1 MILLION RUPEES
MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 5.45 BILLION RUPEES VERSUS 5.02 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: HIKA.NS
(([email protected];))
Hikal Announces US FDA Audit With Zero Observations
May 15 (Reuters) - Hikal Ltd HIKA.NS:
ANNOUNCES US FDA AUDIT WITH ZERO OBSERVATIONS
INSPECTION AT CO'S PHARMACEUTICAL MANUFACTURING FACILITY AT PANOLI CONCLUDED WITH 'ZERO 483 OBSERVATIONS' FROM US FDA
Source text for Eikon: ID:nBSE3RNzxR
Further company coverage: HIKA.NS
(([email protected];;))
May 15 (Reuters) - Hikal Ltd HIKA.NS:
ANNOUNCES US FDA AUDIT WITH ZERO OBSERVATIONS
INSPECTION AT CO'S PHARMACEUTICAL MANUFACTURING FACILITY AT PANOLI CONCLUDED WITH 'ZERO 483 OBSERVATIONS' FROM US FDA
Source text for Eikon: ID:nBSE3RNzxR
Further company coverage: HIKA.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Split
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Hikal do?
Hikal Limited provides a wide range of solutions in the life sciences value chain including manufacturing chemical intermediates, specialty chemicals, active pharma ingredients, and contract research services to global clients.
Who are the competitors of Hikal?
Hikal major competitors are Suven Life Sciences, Piramal Pharma, Suven Pharma, Sun Pharma Adv. Res, Dishman Carbogen Amc, Zenotech Laboratorie, Vivo Bio Tech. Market Cap of Hikal is ₹5,067 Crs. While the median market cap of its peers are ₹3,329 Crs.
Is Hikal financially stable compared to its competitors?
Hikal seems to be less financially stable compared to its competitors. Altman Z score of Hikal is 4.01 and is ranked 5 out of its 8 competitors.
Does Hikal pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Hikal latest dividend payout ratio is 21.26% and 3yr average dividend payout ratio is 17.48%
How has Hikal allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Accounts Receivable
How strong is Hikal balance sheet?
Balance sheet of Hikal is strong. But short term working capital might become an issue for this company.
Is the profitablity of Hikal improving?
The profit is oscillating. The profit of Hikal is ₹74.57 Crs for TTM, ₹69.6 Crs for Mar 2024 and ₹78.38 Crs for Mar 2023.
Is the debt of Hikal increasing or decreasing?
The debt of Hikal is decreasing. Latest debt of Hikal is ₹744 Crs as of Sep-24. This is less than Mar-24 when it was ₹773 Crs.
Is Hikal stock expensive?
Yes, Hikal is expensive. Latest PE of Hikal is 67.95, while 3 year average PE is 43.59. Also latest EV/EBITDA of Hikal is 19.41 while 3yr average is 16.9.
Has the share price of Hikal grown faster than its competition?
Hikal has given lower returns compared to its competitors. Hikal has grown at ~19.1% over the last 2yrs while peers have grown at a median rate of 26.03%
Is the promoter bullish about Hikal?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Hikal is 68.85% and last quarter promoter holding is 68.85%.
Are mutual funds buying/selling Hikal?
The mutual fund holding of Hikal is increasing. The current mutual fund holding in Hikal is 2.93% while previous quarter holding is 2.92%.